2. Search Result
Search Result
Results for "

BDK

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

3

Natural
Products

3

Recombinant Proteins

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156193
    PF-07208254

    		Endogenous Metabolite Cardiovascular Disease
    PF-07208254 is a potent inhibitor of BDK. PF-07208254 improves cardiometabolic endpoints in mice .
    PF-07208254
  • HY-114855
    BT2
    4 Publications Verification

    		 Bcl-2 Family Metabolic Disease
    BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC) . BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM .
    BT2
  • HY-155156
    PF-07238025

    		Endogenous Metabolite Cardiovascular Disease
    PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .
    PF-07238025
  • HY-155157
    PF-07247685

    		Endogenous Metabolite Cardiovascular Disease
    PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .
    PF-07247685
  • HY-159648
    PF-07328948

    		Endogenous Metabolite Cardiovascular Disease
    PF-07328948 is an orally effective BDK (branch chain ketoacid dehydrogenase kinase) inhibitor. PF-07328948 acts as a BCKDH (branch chain ketoacid dehydrogenase) enzyme complex degrader to enhance BCAA (branch chain amino acid) catabolism and has potential inhibitory effects on heart failure .
    PF-07328948
  • HY-169334
    BDK-IN-1

    		Endogenous Metabolite Metabolic Disease
    BDK-IN-1 (compound (-)-43) is a BDK inhibitor with the IC50 of 0.23 μM and the max inhibition of 90%. BDK-IN-1 decreases the level of phospho-E1 and can be used for study of cardiometabolic diseases .
    BDK-IN-1
  • HY-W110242A
    (S)-CPP sodium

    		Others Cardiovascular Disease
    (S)-CPP sodium serves as an inhibitor of the branched-chain α-ketoacid dehydrogenase complex (BCKDC) kinase, commonly referred to as BDK or keto acid dehydrogenase kinase. As a negative regulator of BCKDC activity, the inhibition of BDK by (S)-CPP (with an IC50 of 6.3 μM) results in the activation of the complex and a notable decrease in plasma levels of leucine/isoleucine and valine in wild-type mice.
    (S)-CPP sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: